ALKS
Price
$26.13
Change
-$0.40 (-1.51%)
Updated
Jul 25 closing price
Capitalization
4.55B
3 days until earnings call
VTRS
Price
$9.41
Change
+$0.06 (+0.64%)
Updated
Jul 25 closing price
Capitalization
14.18B
12 days until earnings call
Interact to see
Advertisement

ALKS vs VTRS

Header iconALKS vs VTRS Comparison
Open Charts ALKS vs VTRSBanner chart's image
Alkermes
Price$26.13
Change-$0.40 (-1.51%)
Volume$1.69M
Capitalization4.55B
Viatris
Price$9.41
Change+$0.06 (+0.64%)
Volume$5.03M
Capitalization14.18B
ALKS vs VTRS Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. VTRS commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ALKS: $26.13 vs. VTRS: $9.41)
Brand notoriety: ALKS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 93% vs. VTRS: 40%
Market capitalization -- ALKS: $4.55B vs. VTRS: $14.18B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. VTRS’s [@Pharmaceuticals: Other] market capitalization is $14.18B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • ALKS’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, ALKS is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 7 bearish.
  • VTRS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -10.57% price change this week, while VTRS (@Pharmaceuticals: Other) price change was +5.97% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.55%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +75.03%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.55% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($14.2B) has a higher market cap than ALKS($4.55B). VTRS has higher P/E ratio than ALKS: VTRS (238.80) vs ALKS (8.90). ALKS YTD gains are higher at: -9.145 vs. VTRS (-22.370). VTRS has higher annual earnings (EBITDA): 3.52B vs. ALKS (519M). VTRS has more cash in the bank: 1.18B vs. ALKS (773M). ALKS has less debt than VTRS: ALKS (372M) vs VTRS (18.4B). VTRS has higher revenues than ALKS: VTRS (15.4B) vs ALKS (1.66B).
ALKSVTRSALKS / VTRS
Capitalization4.55B14.2B32%
EBITDA519M3.52B15%
Gain YTD-9.145-22.37041%
P/E Ratio8.90238.804%
Revenue1.66B15.4B11%
Total Cash773M1.18B65%
Total Debt372M18.4B2%
FUNDAMENTALS RATINGS
ALKS vs VTRS: Fundamental Ratings
ALKS
VTRS
OUTLOOK RATING
1..100
569
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
49100
SMR RATING
1..100
3894
PRICE GROWTH RATING
1..100
6356
P/E GROWTH RATING
1..100
531
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (13) in the null industry is significantly better than the same rating for ALKS (99) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that ALKS’s stock grew somewhat faster than VTRS’s over the last 12 months.

ALKS's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for VTRS (94) in the null industry. This means that ALKS’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (56) in the null industry is in the same range as ALKS (63) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for ALKS (53) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSVTRS
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
52%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 17 days ago
75%
Bullish Trend 4 days ago
67%
Declines
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 12 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
Bearish Trend 2 days ago
58%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WMKGX24.36N/A
N/A
WesMark Large Company Fund
NBHAX14.77N/A
N/A
Neuberger Berman Equity Income A
JSVTX15.83N/A
N/A
Janus Henderson Small-Mid Cap Value T
JVTSX77.64N/A
N/A
Janus Henderson Venture S
JUEQX26.89N/A
N/A
JPMorgan US Equity R4